1. Home
  2. AURA vs SGP Comparison

AURA vs SGP Comparison

Compare AURA & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$7.05

Market Cap

713.4M

Sector

Health Care

ML Signal

HOLD

SGP

SpyGlass Pharma Inc. Common Stock

N/A

Current Price

$20.49

Market Cap

650.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AURA
SGP
Founded
2007
2019
Country
United States
United States
Employees
N/A
65
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
713.4M
650.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
AURA
SGP
Price
$7.05
$20.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$20.00
$45.00
AVG Volume (30 Days)
602.2K
170.0K
Earning Date
05-08-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.73
$17.06
52 Week High
$9.54
$30.56

Technical Indicators

Market Signals
Indicator
AURA
SGP
Relative Strength Index (RSI) 52.02 52.74
Support Level $6.58 $17.74
Resistance Level $7.83 $22.86
Average True Range (ATR) 0.35 1.74
MACD 0.02 0.07
Stochastic Oscillator 64.63 45.75

Price Performance

Historical Comparison
AURA
SGP

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

About SGP SpyGlass Pharma Inc. Common Stock

SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Share on Social Networks: